HR 2159

112th CONGRESS
1st Session

H. R. 2159

To reduce disparities and improve access to effective and cost efficient diagnosis and treatment of prostate cancer through advances in testing, research, and education, including through telehealth, comparative effectiveness research, and identification of best practices in patient education and outreach particularly with respect to underserved racial, ethnic and rural populations and men with a family history of prostate cancer, to establish a directive on what constitutes clinically appropriate prostate cancer imaging, and to create a prostate cancer scientific advisory board for the Office of the Chief Scientist at the Food and Drug Administration to accelerate real-time sharing of the latest research and accelerate movement of new medicines to patients.

IN THE HOUSE OF REPRESENTATIVES

June 14, 2011

Mr. TOWNS (for himself, Mr. BROUN of Georgia, Ms. FUDGE, Ms. RICHARDSON, Mr. GERLACH, Ms. MOORE, Mr. MCINTYRE, Mr. RANGEL, Ms. EDDIE BERNICE JOHNSON of Texas, Ms. WILSON of Florida, Ms. NORTON, Mr. THOMPSON of Mississippi, Mr. CARSON of Indiana, Ms. LEE of California, Mr. ISRAEL, and Mr. KING of New York) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committees on Veterans' Affairs and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned


A BILL

To reduce disparities and improve access to effective and cost efficient diagnosis and treatment of prostate cancer through advances in testing, research, and education, including through telehealth, comparative effectiveness research, and identification of best practices in patient education and outreach particularly with respect to underserved racial, ethnic and rural populations and men with a family history of prostate cancer, to establish a directive on what constitutes clinically appropriate prostate cancer imaging, and to create a prostate cancer scientific advisory board for the Office of the Chief Scientist at the Food and Drug Administration to accelerate real-time sharing of the latest research and accelerate movement of new medicines to patients.

SECTION 1. SHORT TITLE.

SEC. 2. FINDINGS.

SEC. 3. PROSTATE CANCER COORDINATION AND EDUCATION.

SEC. 4. PROSTATE CANCER RESEARCH.

SEC. 5. TELEHEALTH AND RURAL ACCESS PILOT PROJECT.

SEC. 6. EDUCATION AND AWARENESS.

SEC. 7. AUTHORIZATION OF APPROPRIATIONS.

END